Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1978 Dec;54(638):799–805.

The immunological evaluation of levamisole treatment in cancer patients

H Verhaegen, J de Cree, A de Beukelaar, W de Cock, F Verbruggen, F Krug
PMCID: PMC2425365

Abstract

The effect of levamisole on different immunological parameters was studied in patients with various malignant diseases.

Levamisole restored tuberculin-negative delayed hypersensitivity reactions and increased the sensitivity to 1-nitro-2,4-dichlorobenzene challenges. It also increased low E-rosette formation of T-lymphocytes and enhanced the clearance of a lipid emulsion by the reticulo-endothelial system.

Levamisole had no effect on serum immunoglobulin levels but increased serum haemolytic complement activity.

Full text

PDF
799

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amery W. K. Double-blind levamisole trial in resectable lung cancer. Ann N Y Acad Sci. 1976;277(00):260–268. doi: 10.1111/j.1749-6632.1976.tb41704.x. [DOI] [PubMed] [Google Scholar]
  2. Anthony H. M., Kirk J. A., Madsen K. E., Mason M. K., Templeman G. H. E and EAC rosetting lymphocytes in patients with carcinoma of bronchus I. Some parameters of the test and of its prognostic significance. Clin Exp Immunol. 1975 Apr;20(1):29–40. [PMC free article] [PubMed] [Google Scholar]
  3. Anthony H. M., Templeman G. H., Madsen K. E., Mason M. K. The prognostic significance of DHS skin tests in patients with carcinoma of bronchus. Cancer. 1974 Dec;34(6):1901–1906. doi: 10.1002/1097-0142(197412)34:6<1901::aid-cncr2820340608>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  4. Bluming A. Z. Commentary: Current status of clinical immunotherapy. Cancer Chemother Rep. 1975 Sep-Oct;59(5):901–913. [PubMed] [Google Scholar]
  5. Brugmans J., Schuermans V., De Cock W., Thienpont D., Janssen P., Verhaegen H., Van Nimmen L., Louwagie A. C., Stevens E. Restoration of host defense mechanisms in man by levamisole. Life Sci. 1973 Dec 1;13(11):1499–1504. doi: 10.1016/0024-3205(73)90137-9. [DOI] [PubMed] [Google Scholar]
  6. Chan S. H., Lee S. K., Simons M. J., Stanley N. F. Levamisole augmentation of lymphocyte hyporesponsiveness to phytohaemagglutinin in patients with pulmonary tuberculosis. Proc Soc Exp Biol Med. 1976 Apr;151(4):716–719. doi: 10.3181/00379727-151-39292. [DOI] [PubMed] [Google Scholar]
  7. Chan S. H., Simons M. J. Letter: Levamisole and lymphocyte responsiveness. Lancet. 1975 May 31;1(7918):1246–1247. doi: 10.1016/s0140-6736(75)92243-6. [DOI] [PubMed] [Google Scholar]
  8. Cheema A. R., Hersh E. M. Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer. 1971 Oct;28(4):851–855. doi: 10.1002/1097-0142(1971)28:4<851::aid-cncr2820280408>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  9. Chirigos M. A., Fuhrman F., Pryor J. Prolongation of chemotherapeutically induced remission of a syneneic murine leukemia by L-2,3,5,6-tetrahydro-6-phenylimidazo[2.1-BETA]thiazole hydrochloride. Cancer Res. 1975 Apr;35(4):927–931. [PubMed] [Google Scholar]
  10. De Cock W., De Crée J., Verhaegen H. Restoration by levamisole of histamine-inhibited E rosette formation of T lymphocytes of patients with allergies. Int Arch Allergy Appl Immunol. 1977;54(2):176–182. doi: 10.1159/000231822. [DOI] [PubMed] [Google Scholar]
  11. Dellon A. L., Potvin C., Chretien P. B. Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment. Cancer. 1975 Mar;35(3):687–694. doi: 10.1002/1097-0142(197503)35:3<687::aid-cncr2820350322>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  12. Eilber F. R., Morton D. L. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970 Feb;25(2):362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  13. Elhilali M. M., Paika K. D., Brosman S., Fahey J. L. Critical evaluation of lymphocyte functions in urological cancer patients. Cancer Res. 1976 Jan;36(1):132–137. [PubMed] [Google Scholar]
  14. Golding H., Golding B., Jacobson R., Lomnitzer R., Koornhof H. J., Rabson A. R. In vitro reversal of cellular unresponsiveness induced by levamisole. Clin Exp Immunol. 1976 Nov;26(2):295–301. [PMC free article] [PubMed] [Google Scholar]
  15. Hoebeke J., Franchi G. Influence of tetramisole and its optical isomers on the mononuclear phagocytic system. Effect on carbon clearance in mice. J Reticuloendothel Soc. 1973 Sep;14(3):317–323. [PubMed] [Google Scholar]
  16. Levo Y., Rotter V., Ramot B. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Biomedicine. 1975 Jun 30;23(6):198–200. [PubMed] [Google Scholar]
  17. Lichtenfeld J. L., Desner M. R., Wiernik P. H., Mardiney M. R., Jr Modulating effects of levamisole (NSC-177023) on human lymphocyte response in vitro. Cancer Treat Rep. 1976 May;60(5):571–574. [PubMed] [Google Scholar]
  18. Lieberman R., Hsu M. Levamisole-mediated restoration of cellular immunity in peripheral blood lymphocytes of patients with immunodeficiency diseases. Clin Immunol Immunopathol. 1976 Jan;5(1):142–146. doi: 10.1016/0090-1229(76)90157-4. [DOI] [PubMed] [Google Scholar]
  19. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  20. Oettgen H. F., Pinsky C. M., Delmonte L. Treatment of cancer with immunomodulators. Med Clin North Am. 1976 May;60(3):511–537. doi: 10.1016/s0025-7125(16)31895-8. [DOI] [PubMed] [Google Scholar]
  21. Perk K., Chirigos M. A., Fuhrman F., Pettigrew H. Some aspects of host response to levamisole after chemotherapy in a murine leukemia. J Natl Cancer Inst. 1975 Jan;54(1):253–256. doi: 10.1093/jnci/54.1.253. [DOI] [PubMed] [Google Scholar]
  22. Ramot B., Biniaminov M., Shoham C., Rosenthal E. Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease. N Engl J Med. 1976 Apr 8;294(15):809–811. doi: 10.1056/NEJM197604082941504. [DOI] [PubMed] [Google Scholar]
  23. Renoux G., Renoux M. Effet immunostimulant d'un Imidothiazole dans l'immunisation des souris contre l'infection par Brucella abortus. C R Acad Sci Hebd Seances Acad Sci D. 1971 Jan 11;272(2):349–350. [PubMed] [Google Scholar]
  24. Rojas A. F., Feierstein J. N., Mickiewicz E., Glait H., Olivari A. J. Levamisole in advanced human breast cancer. Lancet. 1976 Jan 31;1(7953):211–215. doi: 10.1016/s0140-6736(76)91337-4. [DOI] [PubMed] [Google Scholar]
  25. Suciu-Foca N., Buda J., McManus J., Thiem T., Reemtsma K. Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer. Cancer Res. 1973 Oct;33(10):2373–2377. [PubMed] [Google Scholar]
  26. Symoens J., Rosenthal M. Levamisole in the modulation of the immune response: the current experimental and clinical state. J Reticuloendothel Soc. 1977 Mar;21(3):175–221. [PubMed] [Google Scholar]
  27. Tripodi D., Parks L. C., Brugmans J. Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med. 1973 Aug 16;289(7):354–357. doi: 10.1056/NEJM197308162890707. [DOI] [PubMed] [Google Scholar]
  28. Twomey P. L., Catalona W. J., Chretien P. B. Proceedings: Cellular immunity in cured cancer patients. Cancer. 1974 Feb;33(2):435–440. doi: 10.1002/1097-0142(197402)33:2<435::aid-cncr2820330219>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  29. Verhaegen H., De Cock W., De Cree J. The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients. Clin Exp Immunol. 1977 Aug;29(2):311–315. [PMC free article] [PubMed] [Google Scholar]
  30. Verhaegen H., De Cock W., De Cree J., Verbruggen F. Increase of serum complement levels in cancer patients with progressing tumors. Cancer. 1976 Oct;38(4):1608–1613. doi: 10.1002/1097-0142(197610)38:4<1608::aid-cncr2820380427>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  31. Verhaegen H., De Cree J., De Cock W., Verbruggen F. Restoration by levamisole of low E-rosette forming cells in patients suffering from various diseases. Clin Exp Immunol. 1977 Feb;27(2):313–318. [PMC free article] [PubMed] [Google Scholar]
  32. Whitcomb M. E., Merluzzi V. J., Cooperband S. R. The effect of levamisole on human lymphocyte mediator production in vitro. Cell Immunol. 1976 Feb;21(2):272–277. doi: 10.1016/0008-8749(76)90056-3. [DOI] [PubMed] [Google Scholar]
  33. Whitehead R. H., Thatcher J., Teasdale C., Roberts G. P., Hughes L. E. T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet. 1976 Feb 14;1(7955):330–333. doi: 10.1016/s0140-6736(76)90085-4. [DOI] [PubMed] [Google Scholar]
  34. Whittaker M. G., Rees K., Clark C. G. Reduced lymphocyte transformation in breast cancer. Lancet. 1971 May 1;1(7705):892–893. doi: 10.1016/s0140-6736(71)92448-2. [DOI] [PubMed] [Google Scholar]
  35. Wybran J., Fudenberg H. H. Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest. 1973 May;52(5):1026–1032. doi: 10.1172/JCI107267. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES